Skip to content
GLP-1 Scorecard
Menu
Graded #137

Intimate Rose

Intimate Rose is an established US women's and pelvic-health brand that has added an online weight-management program offering compounded GLP-1 medication.

Visit Intimate RoseWe may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Semaglutide
$169/mo (all doses, compounded)
Tirzepatide
$169/mo (all doses, compounded)
Coverage
Coverage not published
Brand-name
Yes

Weigh Intimate Rose against the full graded field on the best semaglutide providers scorecard, or line it up against its closest alternatives.

Factor breakdown

Each of the six graded dimensions. See the methodology.

Cost value65/100
Dose & formulation96/100
Clinical oversight76/100
Labs & monitoring52/100
Fulfillment64/100
Contract terms37/100

Strengths

  • Transparent pricing from 169 dollars per month shown upfront, not gated behind intake
  • Medication and free delivery included, HSA and FSA eligible, no contract
  • Backed by an established women's-health brand using the OpenLoop provider network

Where it loses points

  • State availability not published
  • Oral compounded GLP-1 only; no injectable option shown
  • No specific compounding pharmacy named (network fulfillment via OpenLoop)

Bottom line — Grade C

Best for: Shoppers who want women's-health brand shoppers wanting oral compounded glp-1.

Ranked #137 of 499 on this scorecard. See our top-scoring pick, CoreAge Rx (#1), for comparison.

Closest on the board

The boards grading nearest Intimate Rose — the realistic shortlist.

The 20 boards nearest this one

View full scorecard rankings →

Pricing/verification reflect Intimate Rose's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on Intimate Rose's site. Not medical advice; see our disclosure.

← Back to the scorecard